Vitamin K counteracts the effect of warfarin in liver but not in bone.
Treatment with high dosages of Vitamin K completely inhibited the effect of Warfarin on blood coagulation but had essentially no ability to counteract the effect of Warfarin on the gamma-carboxylation of bone G1a protein (BGP; osteocalcin). Provided that rats received the appropriate dosage of Vitamin K prior to and concurrent with the administration of Warfarin, daily dosages as high as 7.7 mg Warfarin per 100 g body weight had no effect on blood coagulation times. This Warfarin dosage is approximately 150 times higher than the 50 micrograms per 100 g body weight which caused coagulation times to double in rats which did not receive Vitamin K. In dramatic contrast, the dosage of Warfarin required to reduce the gamma-carboxylation status of BGP to one-half normal, 30 micrograms per 100 g body weight, was essentially unaffected by Vitamin K treatment. These results indicate the existence of a major difference between the metabolism of Vitamin K by the hepatocytes which synthesize coagulation factors and the osteoblasts which synthesize BGP. The practical consequence of this difference is that it is now possible to antagonize the action of Vitamin K in osteoblasts, as well as in other cells which have the same Vitamin K metabolism, without affecting blood coagulation times.
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002135:Calcium-Binding Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D008099:Liver / Q000187:drug effects*; D015675:Osteocalcin; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D051381:Rats; D014812:Vitamin K / Q000494:pharmacology*; D014859:Warfarin / Q000037:antagonists & inhibitors*
D002135:Calcium-Binding Proteins; D015675:Osteocalcin; D014812:Vitamin K; D014859:Warfarin